Uridul Hubrain Reports 10 Billion KRW Investment Gains Last Year... "Maximizing Investment Efficiency"

[Asia Economy Reporter Hyunseok Yoo] Wooridle Hubrain announced on the 18th that it realized investment profits exceeding 10 billion KRW based on preliminary financial results as of the end of last year.

Wooridle Hubrain officially entered value stock discovery starting with the acquisition of 7.5 billion KRW worth of shares in the medical analysis device company ‘VIVIVI’ in 2019. Additionally, on the 16th, it revealed an additional investment of 3.1 billion KRW. The valuation gain from ‘VIVIVI’ alone is close to 2 billion KRW. The company expects the investment profits to further expand due to the positive outlook on the increase in supply sales of COVID-19 diagnostic kits by ‘VIVIVI’ and the future rise in corporate value.

Moreover, the valuation gain on the 30 billion KRW convertible bonds (CB) of ‘Aprogen KIC’, acquired in October last year, amounts to 3 billion KRW, exceeding 10% of the investment amount. The valuation gain on the 7 billion KRW CB of ‘ITEK’, acquired in November of the same year, is about 1.6 billion KRW. The bio company ‘Aprogen KIC’ is a unicorn company recognized with a corporate value exceeding 1 trillion KRW, and the semiconductor test house ‘ITEK’ is securing business stability and growth momentum through steady facility investments.

Wooridle Hubrain operates pharmaceutical and medical device supply businesses. Its major subsidiary is ‘Greenbell Systems’, which mainly generates revenue from the storage business, with a 95.3% stake. Through its affiliate ‘Ailat Investment Association’, it forms new technology and value investment funds, pursuing both stability and profitability in the M&A market, thereby maximizing the discovery of promising investment destinations and investment efficiency.